Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 20, 2009

OriGene Acquires Marligen to Fortify Gene-Centric Toolbox

  • OriGene Technologies is taking over Marligen Biosciences to enhance its gene-centric product portfolio. Marligen adds an array of assay panels and custom assays for drug discovery.

    Marligen provides protein and gene-expression profiling assays and testing services for the Luminex xMAP® platform as well as DNA and RNA purification kits. OriGene aims to couple these assays and reagents with its high-throughput mAb production capabilities to further develop high-quality panels and offer customization to hasten and increase efficiencies for drug discovery.

    OriGene's mammalian cell-expressed proteins reportedly maintain authentic protein structure, post-translational modifications, and functions. The firm’s product line includes what is reportedly the largest cDNA and shRNA clone collections of over 5,000 purified human proteins, high-quality mAbs to human proteins, 100,000 highly validated human tissues, and qPCR arrays. OriGene also provides antibody-validation products including genome-wide tagged antigen standards and extensive IHC slides derived from its tissue collection.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »